Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer’s disease
Our data suggest that among different markers relevant to barrier dysfunction, plasma S100β is the most promising diagnostic biomarker for ADNC. Further investigation is necessary to assess how plasma S100β levels relate to these changes and whether they may predict clinical outcomes, particularly in the prodromal and early stages of AD.
Authors
- Bryan Maloney (ORCID: https://orcid.org/0000-0003-2364-9649)
- Peter T. Nelson (ORCID: https://orcid.org/0000-0002-6161-1265)
- Wijitra Chumboatong
- Erin L. Abner (ORCID: https://orcid.org/0000-0002-9566-4111)
- Geetika Nehra (ORCID: https://orcid.org/0000-0003-4376-5313)
- Anika M. S. Hartz
- Rebecca Smith
- Björn Bauer
Institutions
- University of Kentucky (US)
Publication Details
- Journal
- Fluids and Barriers of the CNS
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1186/s12987-024-00615-8
- Citations
- 9
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.48
Funders
- National Institutes of Health